SEC Comment Letter 0000000000-24-001087 to BriaCell Therapeutics Corp. (BCTX)
BriaCell Therapeutics Corp.
Date: Jan. 29, 2024 · CIK: 0001610820 · Accession: 0000000000-24-001087
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276650
Letter
United States securities and exchange commission logo January 29, 2024 William V. Williams Chief Executive Officer BriaCell Therapeutics Corp. Suite 300, 235 15th Street West Vancouver, BC V7T 2X1 Re:BriaCell Therapeutics Corp. Registration Statement on Form S-3 Filed January 22, 2024 File No. 333-276650 Dear William V. Williams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Avital Perlman, Esq.
Show Raw Text
United States securities and exchange commission logo
January 29, 2024
William V. Williams
Chief Executive Officer
BriaCell Therapeutics Corp.
Suite 300, 235 15th Street
West Vancouver, BC V7T 2X1
Re:BriaCell Therapeutics Corp.
Registration Statement on Form S-3
Filed January 22, 2024
File No. 333-276650
Dear William V. Williams:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Avital Perlman, Esq.